Trump's NIH Pick Bhattacharya's Challenges to Include Research Funding Cuts
Republicans who control the Senate have largely embraced the nomination, arguing that Bhattacharya's skepticism of federal pandemic policies reflects the need for reform at the NIH. All of Trump's high-level nominations have been confirmed,
Ripple effects of the Trump administration’s crackdown on U.S. medical research promise to reach every corner of America.
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.
Studies that touch on LGBT+ health, gender identity and DEI in the biomedical workforce could be terminated, according to ...
The Trump administration’s orders have created more turmoil and damage at the National Institutes of Health than was ...
“The menopause transition specifically might be an important key to help us unlock the biology of Alzheimer’s disease, and ...
Health economist Jay Bhattacharya, who drew censure for controversial views on COVID-19, vows to provide funding but is short ...
Like the nearby EPA, the National Institute of Environmental Health Sciences fired a number of early-career “probationary” ...
Science needs free speech! That was the resounding message from NIH nominee Jay Bhattacharya. During his confirmation hearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback